Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC (RAISE)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05718323 |
Recruitment Status :
Recruiting
First Posted : February 8, 2023
Last Update Posted : April 5, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
SCLC,Extensive Stage SLFN11-positive | Drug: Niraparib | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 44 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Single-arm Phase II Trial of the Addition of Niraparib to Anti-PD-L1 Antibody Maintenance in Patients With SLFN11-positive, Extensive-disease Small Cell Lung Cancer. |
Actual Study Start Date : | December 20, 2023 |
Estimated Primary Completion Date : | May 2025 |
Estimated Study Completion Date : | October 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: Treatment Arm |
Drug: Niraparib
200 mg orally once daily, until PD 300 mg once daily if body weight ≥77 kg and platelets ≥150 g/L, until PD |
- Progression-free survival (PFS) rate at 3 months by investigator assessment (according to RECIST v1.1) [ Time Frame: From date of enrolment until 3 months post-enrolment ]Defined as the rate of patients without a PFS event at 3 months after enrolment
- Progression-free survival (PFS) [ Time Frame: From the date of enrolment until last tumour assessment (approximately 25-30 months after the enrolment of the first patient) ]Defined as the time from the date of enrolment until documented progression
- Overall survival (OS) [ Time Frame: From the date of enrolment until death from any cause (approximately 25-30 months after the enrolment of the first patient) ]Defined as the time from the date of enrolment until death from any cause
- Disease control rate (DCR) by investigator assessment (according to RECIST v1.1) [ Time Frame: approximately 25-30 months after the enrolment of the first patient ]Defined as the rate of patients, among all enrolled patients, that achieve a complete response (CR) or partial response (PR) or stabilisation of disease (SD, at least at week 6) by investigator assessment
- Adverse events according to CTCAE v5.0 [ Time Frame: From the date of enrolment until last patient last visit (approximately 25- 30 months after enrolment of the first patient) ]Adverse events according to CTCAE v5.0 (any-cause as well as treatment-related) including adverse events leading to dose interruptions, withdrawal of protocol treatment and death
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Inclusion criteria for SLFN11-expression testing
- Written IC part 1: for SLFN11-screening must be signed and dated by the patient and the investigator prior to sending any tumour material to the central laboratory.
- Histologically or cytologically confirmed ED-SCLC (stage IV according to the 8th TNM classification).
- Availability of FFPE tumour tissue for screening.
Inclusion criteria for trial participation
- Written IC part 2: for trial participation must be signed and dated by the patient and the investigator prior to any trial-related intervention.
- High SLFN11-expression on FFPE tumour material:
SLFN11-expression is determined at the central screening laboratory in Basel. Overexpression is defined as detectable protein expression by IHC in ≥20% of tumour cells.
- Patients must have received standard first-line chemo-immunotherapy, consisting of 4 cycles of platinum-etoposide chemotherapy in combination with an anti-PD-L1 antibody (atezolizumab or durvalumab). Patients who started the immunotherapy at chemotherapy cycle 2 are eligible.
- ED-SCLC must not have progressed during or after standard chemo-immunotherapy (as per RECIST v1.1).
- Patients must be candidates for ongoing maintenance treatment with immune-checkpoint inhibition.
- Adequate haematological function:
- Adequate renal function:
- Adequate liver function:
- ECOG PS 0-2
- Age ≥18 years
- Women of childbearing potential, including women who had their last menstruation in the last 2 years, must have a negative urinary or serum pregnancy test within 4 weeks before enrolment and within 3 days before treatment start.
Exclusion Criteria:
- Symptomatic brain metastases
- Any clinically active cancer, other than SCLC Exception: malignancies with negligible risk of metastases or death (e.g. 5-year OS rate of >90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localised prostate cancer, ductal carcinoma in situ, or stage I uterine cancer. Hormonal therapy for non-metastatic prostate or ductal carcinoma in situ is allowed.
Consolidating thoracic radiotherapy. Palliative radiotherapy to the brain or to bones is allowed.
- History of idiopathic pulmonary fibrosis, organising pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan.
- Any lung disease requiring systemic steroids in doses of >10 mg prednisolone (or equivalent dose of other steroid).
- Any serious concomitant systemic disorders (for example active infection, unstable cardiovascular disease) which in the opinion of the investigator would compromise the patient's ability to complete the trial or interfere with the evaluation of the efficacy and safety of the protocol treatment.
- Inadequately controlled hypertension, defined as systolic blood pressure >150 mmHg and/or diastolic blood pressure >95 mmHg.
The patient must be considered stable and hypertension medically controlled.
- History of myelodysplastic syndrome/acute myeloid leukemia (MDS/AML).
- Prior Reversible Encephalopathy Syndrome (PRES)
- Severe renal or hepatic impairment.
- Any clinically significant gastrointestinal (GI) abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach and/or bowels.
- Treated with live vaccine within 30 days before enrolment.
- Hypersensitivity to niraparib or any of its excipients (e.g., tartrazine).
- Women who are pregnant or in the period of lactation.
- Sexually active men and women of childbearing potential who are not willing to use an effective contraceptive method during the trial and within the required timelines after last dose of niraparib treatment.
- Judgment by the investigator that the patient is unlikely to comply with trial procedures, restrictions and requirements.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05718323
Contact: Heidi Roschitzki, PhD | +41 31 511 94 00 | heidi.roschitzki@etop.ibcsg.org | |
Contact: Susanne Roux | RAISE@etop.ibcsg.org |
Study Chair: | Markus Joerger, MD-PhD | Department of Medical Oncology, Cantonal Hospital St.Gallen |
Responsible Party: | ETOP IBCSG Partners Foundation |
ClinicalTrials.gov Identifier: | NCT05718323 |
Other Study ID Numbers: |
ETOP 23-22 |
First Posted: | February 8, 2023 Key Record Dates |
Last Update Posted: | April 5, 2024 |
Last Verified: | April 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Niraparib Poly(ADP-ribose) Polymerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |